Rury R Holman

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 45

Top Topics

Cardiovascular Disease

Top Venues

Diabetes, obesity & metabolism

Nature communications

PharmacoEconomics

This page only lists publications with an associated author ORCID identifier.

Publications

Ni Gao, Helen A Dakin, Rury R Holman, Lee-Ling Lim, José Leal, Philip Clarke
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management. PharmacoEconomics 42 (9) (2024)
Ni Gao, Helen A Dakin, Rury R Holman, Lee-Ling Lim, José Leal, Philip Clarke
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management. PharmacoEconomics 42 (9) (2024)
Ni Gao, Helen A Dakin, Rury R Holman, Lee-Ling Lim, José Leal, Philip Clarke
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management. PharmacoEconomics (2024)
Ni Gao, Helen A Dakin, Rury R Holman, Lee-Ling Lim, José Leal, Philip Clarke
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management. PharmacoEconomics 42 (9) (2024)
Ni Gao, Helen A Dakin, Rury R Holman, Lee-Ling Lim, José Leal, Philip Clarke
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management. PharmacoEconomics 42 (9) (2024)
Nantia Othonos, Riccardo Pofi, Anastasia Arvaniti, Sarah White, Ilaria Bonaventura, Nikolaos Nikolaou, Ahmad Moolla, Thomas Marjot, Roland H Stimson, André P van Beek, Martijn van Faassen, Andrea M Isidori, Elizabeth Bateman, Ross Sadler, Fredrik Karpe, Paul M Stewart, Craig Webster, Joanne Duffy, Richard Eastell, Fatma Gossiel, Thomas Cornfield, Leanne Hodson, K Jane Escott, Andrew Whittaker, Ufuk Kirik, Ruth L Coleman, Charles A B Scott, Joanne E Milton, Olorunsola Agbaje, Rury R Holman, Jeremy W Tomlinson
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial. Nature communications 14 (1) (2023)
Nantia Othonos, Riccardo Pofi, Anastasia Arvaniti, Sarah White, Ilaria Bonaventura, Nikolaos Nikolaou, Ahmad Moolla, Thomas Marjot, Roland H Stimson, André P van Beek, Martijn van Faassen, Andrea M Isidori, Elizabeth Bateman, Ross Sadler, Fredrik Karpe, Paul M Stewart, Craig Webster, Joanne Duffy, Richard Eastell, Fatma Gossiel, Thomas Cornfield, Leanne Hodson, K Jane Escott, Andrew Whittaker, Ufuk Kirik, Ruth L Coleman, Charles A B Scott, Joanne E Milton, Olorunsola Agbaje, Rury R Holman, Jeremy W Tomlinson
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial. Nature communications 14 (1) (2023)
Nantia Othonos, Riccardo Pofi, Anastasia Arvaniti, Sarah White, Ilaria Bonaventura, Nikolaos Nikolaou, Ahmad Moolla, Thomas Marjot, Roland H Stimson, André P van Beek, Martijn van Faassen, Andrea M Isidori, Elizabeth Bateman, Ross Sadler, Fredrik Karpe, Paul M Stewart, Craig Webster, Joanne Duffy, Richard Eastell, Fatma Gossiel, Thomas Cornfield, Leanne Hodson, K Jane Escott, Andrew Whittaker, Ufuk Kirik, Ruth L Coleman, Charles A B Scott, Joanne E Milton, Olorunsola Agbaje, Rury R Holman, Jeremy W Tomlinson
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial. Nature communications 14 (1) (2023)
Nantia Othonos, Riccardo Pofi, Anastasia Arvaniti, Sarah White, Ilaria Bonaventura, Nikolaos Nikolaou, Ahmad Moolla, Thomas Marjot, Roland H Stimson, André P van Beek, Martijn van Faassen, Andrea M Isidori, Elizabeth Bateman, Ross Sadler, Fredrik Karpe, Paul M Stewart, Craig Webster, Joanne Duffy, Richard Eastell, Fatma Gossiel, Thomas Cornfield, Leanne Hodson, K Jane Escott, Andrew Whittaker, Ufuk Kirik, Ruth L Coleman, Charles A B Scott, Joanne E Milton, Olorunsola Agbaje, Rury R Holman, Jeremy W Tomlinson
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial. Nature communications 14 (1) (2023)
Nantia Othonos, Riccardo Pofi, Anastasia Arvaniti, Sarah White, Ilaria Bonaventura, Nikolaos Nikolaou, Ahmad Moolla, Thomas Marjot, Roland H Stimson, André P van Beek, Martijn van Faassen, Andrea M Isidori, Elizabeth Bateman, Ross Sadler, Fredrik Karpe, Paul M Stewart, Craig Webster, Joanne Duffy, Richard Eastell, Fatma Gossiel, Thomas Cornfield, Leanne Hodson, K Jane Escott, Andrew Whittaker, Ufuk Kirik, Ruth L Coleman, Charles A B Scott, Joanne E Milton, Olorunsola Agbaje, Rury R Holman, Jeremy W Tomlinson
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial. Nature communications 14 (1) (2023)
Nantia Othonos, Riccardo Pofi, Anastasia Arvaniti, Sarah White, Ilaria Bonaventura, Nikolaos Nikolaou, Ahmad Moolla, Thomas Marjot, Roland H Stimson, André P van Beek, Martijn van Faassen, Andrea M Isidori, Elizabeth Bateman, Ross Sadler, Fredrik Karpe, Paul M Stewart, Craig Webster, Joanne Duffy, Richard Eastell, Fatma Gossiel, Thomas Cornfield, Leanne Hodson, K Jane Escott, Andrew Whittaker, Ufuk Kirik, Ruth L Coleman, Charles A B Scott, Joanne E Milton, Olorunsola Agbaje, Rury R Holman, Jeremy W Tomlinson
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial. Nature communications 14 (1) (2023)
Moritz J Hundertmark, Amanda I Adler, Charalambos Antoniades, Ruth L Coleman, Julian Leether Griffin, Rury R Holman, Hanan Lamlum, Jisoo Lee, Daniel Massey, Jack J J J Miller, Joanne E Milton, Shveta Monga, Ferenc E Mózes, Areesha Nazeer, Betty Raman, Oliver J Rider, Christopher T Rodgers, Ladislav Valkovič, Eleanor Wicks, Masliza Mahmod, Stefan Neubauer
Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial. Circulation (2023)
Nantia Othonos, Riccardo Pofi, Anastasia Arvaniti, Sarah White, Ilaria Bonaventura, Nikolaos Nikolaou, Ahmad Moolla, Thomas Marjot, Roland H Stimson, André P van Beek, Martijn van Faassen, Andrea M Isidori, Elizabeth Bateman, Ross Sadler, Fredrik Karpe, Paul M Stewart, Craig Webster, Joanne Duffy, Richard Eastell, Fatma Gossiel, Thomas Cornfield, Leanne Hodson, K Jane Escott, Andrew Whittaker, Ufuk Kirik, Ruth L Coleman, Charles A B Scott, Joanne E Milton, Olorunsola Agbaje, Rury R Holman, Jeremy W Tomlinson
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial. Nature communications 14 (1) (2023)
Beverley M Shields, Raphael Sonabend, Catherine D Angwin, Fiona Warren, William E Henley, Andrew J Farmer, Naveed Sattar, Rury R Holman, Angus G Jones, Ewan R Pearson, Andrew T Hattersley, null null
Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study. Nature medicine (2022)
Matthew W Segar, Kershaw V Patel, Anne S Hellkamp, Muthiah Vaduganathan, Yuliya Lokhnygina, Jennifer B Green, Siu-Hin Wan, Ahmed A Kolkailah, Rury R Holman, Eric D Peterson, Vaishnavi Kannan, Duwayne L Willett, Darren K McGuire, Ambarish Pandey
Validation of the WATCH-DM and TRS-HF DM Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis. Journal of the American Heart Association 11 (11) (2022)
Stephen A Williams, Rachel Ostroff, Michael A Hinterberg, Josef Coresh, Christie M Ballantyne, Kunihiro Matsushita, Christian E Mueller, Joan Walter, Christian Jonasson, Rury R Holman, Svati H Shah, Naveed Sattar, Roy Taylor, Michael Ernest John Lean, Shintaro Kato, Hiroaki Shimokawa, Yasuhiko Sakata, Kotaro Nochioka, Chirag R Parikh, Steven G Coca, Torbjørn Omland, Jessica Chadwick, David Astling, Yolanda Hagar, Natasha Kureshi, Kelsey Loupy, Clare Paterson, Jeremy Primus, Missy Simpson, Nelson P Trujillo, Peter Ganz
A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. Science translational medicine 14 (639) (2022)
Andrew P McGovern, Michael Hogg, Beverley M Shields, Naveed A Sattar, Rury R Holman, Ewan R Pearson, Andrew T Hattersley, Angus G Jones, John M Dennis, null null
Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ open diabetes research & care 8 (1) (2021)
Malgorzata Wamil, Ruth L Coleman, Amanda I Adler, John J V McMurray, Rury R Holman
Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89. Diabetes care 44 (8) (2021)
Lindsay E Clegg, Yankang Jing, Robert C Penland, David W Boulton, Adrian F Hernandez, Rury R Holman, Jiten Vora
Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials. Diabetes, obesity & metabolism 23 (5) (2021)
Marcus Lind, Henrik Imberg, Ruth L Coleman, Olle Nerman, Rury R Holman
Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Diabetes care (2021)
Abhinav Sharma, Yinggan Zheng, Justin A Ezekowitz, Cynthia M Westerhout, Jacob A Udell, Shaun G Goodman, Paul W Armstrong, John B Buse, Jennifer B Green, Robert G Josse, Keith D Kaufman, Darren K McGuire, Giuseppe Ambrosio, Lee-Ming Chuang, Renato D Lopes, Eric D Peterson, Rury R Holman
Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. Diabetes care (2021)
Annemarie B van der Aart-van der Beek, Lindsay E Clegg, Robert C Penland, David W Boulton, C David Sjöström, Robert J Mentz, Rury R Holman, Hiddo J Lambers Heerspink
Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial. Diabetes, obesity & metabolism 22 (12) (2020)
Helen A Dakin, José Leal, Andrew Briggs, Philip Clarke, Rury R Holman, Alastair Gray
Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data. Medical decision making : an international journal of the Society for Medical Decision Making 40 (4) (2020)
Laurie L Baggio, Elodie M Varin, Jacqueline A Koehler, Xiemin Cao, Yuliya Lokhnygina, Susanna R Stevens, Rury R Holman, Daniel J Drucker
Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans. Nature communications 11 (1) (2020)
Louise A Donnelly, John M Dennis, Ruth L Coleman, Naveed Sattar, Andrew T Hattersley, Rury R Holman, Ewan R Pearson
Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study. Diabetes care 43 (10) (2020)
Nienke M A Idzerda, Lindsay E Clegg, Adrian F Hernandez, George L Bakris, Robert C Penland, David W Boulton, M Angelyn Bethel, Rury R Holman, Hiddo J Lambers Heerspink
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. Diabetes, obesity & metabolism 22 (5) (2020)
Matthew C Riddle, Lawrence Blonde, Ulagamadesan Venkatesan, Edward W Gregg, Rury R Holman, John M Lachin, Gregory A Nichols, Alexander Turchin, William T Cefalu
Diabetes Care Editors' Expert Forum 2018: Managing Big Data for Diabetes Research and Care. Diabetes care 42 (6) (2020)
Ruth L Coleman, Alastair M Gray, Uli C Broedl Md, David H Fitchett, Jyothis T George, Hans J Woerle, Bernard Zinman, Rury R Holman
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels? Diabetes, obesity & metabolism 22 (7) (2020)
Chitrabhanu Ballav, Archana Dhere, Irene Kennedy, Olorunsola F Agbaje, Sarah White, Rachel Franklin, Bolette Hartmann, Jens J Holst, Rury R Holman, Katharine R Owen
Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients. Endocrinology, diabetes & metabolism 3 (3) (2020)
Stephen P Juraschek, Jiun-Ruey Hu, Jennifer L Cluett, Anthony M Ishak, Carol Mita, Lewis A Lipsitz, Lawrence J Appel, Nigel S Beckett, Ruth L Coleman, William C Cushman, Barry R Davis, Greg Grandits, Rury R Holman, Edgar R Miller, Ruth Peters, Jan A Staessen, Addison A Taylor, Lutgarde Thijs, Jackson T Wright, Kenneth J Mukamal
Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension : A Systematic Review and Individual Participant-based Meta-analysis. Annals of internal medicine 174 (1) (2020)
Shelby D Reed, Shelby D Reed, Rishi Patel, Oliver Rivero-Arias, Yanhong Li, Kevin A Schulman, Robert M Califf, Rury R Holman, Alastair M Gray
Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. Diabetes care 43 (10) (2020)
Ulagamadesan Venkatesan, Ruth L Coleman, Charles A B Scott, Shishi Xu, Jaakko Tuomilehto, Lars Ryden, Rury R Holman, null null
Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. Diabetes care 43 (9) (2020)
Ernesto Maddaloni, Ruth L Coleman, Paolo Pozzilli, Rury R Holman
Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85). Diabetes, obesity & metabolism 21 (9) (2019)
M Angelyn Bethel, Rishi A Patel, Vivian P Thompson, Peter Merrill, Shelby D Reed, Yanhong Li, Sara Ahmadi, Brian G Katona, Stephanie M Gustavson, Peter Ohman, Nayyar Iqbal, Robert F Gagel, Adrian F Hernandez, John B Buse, Rury R Holman, null null
Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes care 42 (6) (2019)
Eberhard Standl, Susanna R Stevens, Yuliya Lokhnygina, M Angelyn Bethel, John B Buse, Stephanie M Gustavson, Aldo P Maggioni, Robert J Mentz, Adrian F Hernandez, Rury R Holman, null null
Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes care 43 (3) (2019)
M Angelyn Bethel, Robert J Mentz, Peter Merrill, John B Buse, Juliana Chung Ngor Chan, Shaun G Goodman, Nayyar Iqbal, Neli Jakuboniene, Brian Katona, Yuliya Lokhnygina, Renato D Lopes, Aldo P Maggioni, Peter Ohman, Tsvetalina Tankova, George L Bakris, Adrian F Hernandez, Rury R Holman
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes care 43 (2) (2019)
Shelby D Reed, Yanhong Li, Helen A Dakin, Frauke Becker, Shelby D Reed, Stephanie M Gustavson, Bernt Kartman, Eric Wittbrodt, Robert J Mentz, Neha J Pagidipati, M Angelyn Bethel, Alastair M Gray, Rury R Holman, Adrian F Hernandez, null null
Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes care 43 (2) (2019)
Eberhard Standl, Jennifer B Green, Rury R Holman, null null
Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care 2019;42:157-163. Diabetes care 42 (6) (2019)
Xiqian Huo, Rury R Holman, Jane Armitage
Comment on Kim et al. The Effect of a Smartphone-Based, Patient-Centered Diabetes Care System in Patients With Type 2 Diabetes: A Randomized, Controlled Trial for 24 Weeks. Diabetes Care 2019;42:3-9. Diabetes care 42 (7) (2019)
Raphael Sonabend, William E Henley, Andrew P McGovern, Andrew J Farmer, Naveed Sattar, Rury R Holman, Ewan R Pearson, Andrew T Hattersley, Beverley M Shields, Angus G Jones, null null
Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017. Diabetes, obesity & metabolism 21 (7) (2019)
M Angelyn Bethel, Samuel S Engel, Susanna R Stevens, Yuliya Lokhnygina, Jie Ding, Robert G Josse, Michael Alvarsson, Irene Hramiak, Jennifer B Green, Eric D Peterson, Rury R Holman, null null
Progression of glucose-lowering diabetes therapy in TECOS. Endocrinology, diabetes & metabolism 2 (1) (2018)
Joakim Alfredsson, Jennifer B Green, Susanna R Stevens, Shelby D Reed, Paul W Armstrong, M Angelyn Bethel, Samuel S Engel, Darren K McGuire, Frans Van de Werf, Irene Hramiak, Harvey D White, Eric D Peterson, Rury R Holman, null null
Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. Diabetes, obesity & metabolism 20 (10) (2018)
Shelby D Reed, Yanhong Li, Jose Leal, Larry Radican, Amanda I Adler, Joakim Alfredsson, John B Buse, Jennifer B Green, Keith D Kaufman, Axel Riefflin, Frans Van de Werf, Eric D Peterson, Alastair M Gray, Rury R Holman, null null
Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, obesity & metabolism 20 (7) (2018)
Timothy M E Davis, Hillary Mulder, Yuliya Lokhnygina, Pablo Aschner, Lee-Ming Chuang, Carlos A Raffo Grado, Eberhard Standl, Eric D Peterson, Rury R Holman, null null
Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, obesity & metabolism 20 (6) (2018)
Lindsay E Clegg, Hiddo J Lambers Heerspink, Robert C Penland, Weifeng Tang, David W Boulton, Srinivas Bachina, Robert D Fox, Peter Fenici, Marcus Thuresson, Robert J Mentz, Adrian F Hernandez, Rury R Holman
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. Diabetes care 42 (2) (2018)